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ABSTRACT
CONTEXT: Neurofibromatosis type 1 (NF-1) is the most prevalent autosomal dominant genetic disorder among humans. Moyamoya disease is a 
cerebral vasculopathy that is only rarely observed in association with NF-1, particularly in the pediatric age range. The present study reports an 
occurrence of this association in an infant.
CASE REPORT: An eight-month-old female presented convulsive seizures with clonic movements. The patient suffered an ischemic stroke with 
hemiparesis. Magnetic resonance imaging revealed radiological findings compatible with moyamoya disease. The diagnosis of NF-1 was made at the 
age of 20 months.
CONCLUSION: Despite the rarity of this association in childhood, children with focal neurological symptoms and a diagnosis of NF-1 deserve to be 
investigated for moyamoya syndrome.
RESUMO
CONTEXTO: Neurofibromatose tipo 1 (NF-1) é a doença genética autossômica dominante mais prevalente no ser humano. A doença de moyamoya 
é uma vasculopatia cerebral que raramente se encontra associada à NF-1, particularmente na faixa etária pediátrica. Este estudo descreve a 
ocorrência desta associação em um lactente. 
RELATO DE CASO: Paciente feminina, aos oito meses de idade, apresentou quadro de crise convulsiva com movimentos clônicos. Evoluiu com 
acidente vascular encefálico isquêmico e com hemiparesia à direita. Ressonância nuclear magnética mostrou achados compatíveis com a doença 
de moyamoya. O diagnóstico de NF-1 foi realizado aos 20 meses de vida.
CONCLUSÃO: Apesar da raridade desta associação na faixa etária infantil, crianças com sintomas neurológicos focais e diagnóstico de NF-1 
merecem ser investigadas para síndrome de moyamoya.
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INTRODUCTION 
Neurofibromatosis type 1 (NF-1) is a multisystemic genetic disor-
der that displays important cutaneous manifestations such as café-au-
lait spots, freckles and neurofibromas. Despite variable clinical expres-
sion, mutation of the NF-1 gene is considered to be the most com-
mon de novo spontaneous autosomal dominant genetic alteration in 
human beings, with complete penetrance.1 The incidence of NF-1 is 
approximately one in 2,500 births, affecting all races. About 80,000 
cases are estimated to exist currently in Brazil, and about 1.5 million 
worldwide.1,2 
The NF-1 gene is located on the long arm of chromosome 17, and 
more precisely, in the 17q11.2 band. This gene codes for neurofibro-
min, a protein that acts during nervous tissue growth remodeling.2 
Recent studies have also demonstrated the presence of neurofibromin 
on the walls of vascular endothelial cells and in vascular smooth mus-
cle cells.3 
Moyamoya disease (MMD) is a rare inherited cerebral disorder of 
unknown etiology characterized by obliteration of the internal carotid 
artery and its branches, with the concomitant development of an ab-
normal network of collateral vessels. Moyamoya syndrome (MMS), 
an acquired form of MMD, also displays the angiographic pattern of 
MMD, although it is usually associated with different risk factors such 
as NF-1, Down syndrome and previous cranial irradiation, among 
others.4 Associations between NF-1 and vascular disorders are not un-
common, although associations between NF-1 and specific cerebro-
vascular disorders such as MMS are far less frequent.5,6 
The objective of this study was to report on the case of a patient 
with NF-1 and MMS. This paper also provides a brief review of the 
main clinical and radiological aspects of this association. We conduct-
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ed a systematic search in the PubMed, Cochrane Library, Lilacs (Litera-
tura Latino Americana e do Caribe em Ciências da Saúde) and SciELO 
(Scientific Electronic Library Online) databases. The results obtained 
are shown in Table 1.
CASE REPORT 
An eight-month-old Afro-descendant girl was referred to the emer-
gency room of the University Hospital due to convulsive 5-10 minute 
seizures characterized by mucosal pallor, clonic movement to the right 
and right-sided head version. The patient presented postictal somno-
lence. No fever was observed at the time of the seizures. A cerebrospi-
nal fluid tap yielded normal results. Brain magnetic resonance imaging 
(MRI) revealed asymmetry of the hemispheres, with hemiatrophy on 
the left (Figure 1A) and signs of internal carotid occlusion in the supra-
clinoid and basilar portions, with marked collateral circulation through 
perforating vessels, with a moyamoya pattern (Figures 1B to 1F). Hemi-
paresis was most evident in the right upper limb.
A diagnosis of ischemic stroke was made based on the clinical and 
radiological findings. Thrombophilia testing was negative. At one year 
and eight months of age, she was referred to the medical genetics ser-
vice due to the presence of skin lesions, delayed motor development and 
facial dysmorphism. Physical examination revealed several café-au-lait 
spots (larger than 0.5 cm) and cutaneous neurofibromas. At two years 
of age, the patient presented facial paralysis with slight facial asymmetry 
of peripheral pattern. Her mother also fulfilled the diagnostic criteria for 
NF-1. The girl is the first child of non-consanguineous healthy parents. 
Regarding her neuropsychomotor development, she was able to hold 
her head up at the age of seven months, spoke her first words at the age 
of one year and seven months and sat up unsupported at the age of one 
year and nine months. The child is currently under clinical surveillance, 
and persists with motor deficits.
DISCUSSION 
NF-1 occurs most frequently during childhood, and its diagnosis 
is based on the clinical criteria established by the National Institutes 
of Health (NIH) Consensus Development Conference.2,7 For a defini-
tive diagnosis of NF-1, two or more of the following clinical character-
Database Search strategy Results
PubMed Neurofibromatosis type 1 [MeSH] AND moyamoya 
disease [MeSH]
28 articles
23 case reports
2 original articles
2 reviews
1 case series
Lilacs Neurofibromatosis type 1 AND moyamoya disease No articles
SciELO Neurofibromatosis type 1 AND moyamoya disease 1 case report
Cochrane Neurofibromatosis type 1 AND moyamoya disease No articles
Table 1. Systematic review of the literature
Figures 1A-1F. Magnetic resonance imaging performed with Philips 3.0 Tesla apparatus showing FLAIR (fluid-attenuated inversion recovery) images (A), 
T2 (B), post-contrast T1 (C and D) and angioresonance of intracranial and cervical vessels (E and F). Asymmetry of the brain hemisphere can be seen in 
A, with marked atrophy on the left, distortion of the gyri and prominence of the sulci, involving the cortex and the left frontotemporal-parietal white matter, 
while sparing the ipsilateral occipital region (large arrow). B, C and D show exuberant tortuous collateral circulation above the occlusion of the supraclinoid 
internal carotids. E and F show occlusion of the internal carotids in the supraclinoid region and above the basilar artery, associated with exuberant and 
tortuous collateral circulation in perforating vessels (dotted and small arrows). 
LEGEND: LICA = left internal carotid artery; RICA = right internal carotid artery; BA = basilar artery; RCCA = right common carotid artery; LCCA = left common carotid artery.
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istics must be present: I) six or more café-au-lait spots with a diameter 
of about 5 mm in prepubertal individuals, or with a diameter of more 
than 15 mm in postpubertal individuals; II) two or more neurofibromas 
of any type or one plexiform neurofibroma, based on clinical and histo-
logical parameters; III) freckles in an axillary or inguinal region; IV) op-
tic glioma; V) two or more Lisch nodules (pigmented iris hamartomas); 
VI) a distinct bone lesion such as pseudarthrosis of a long bone or dys-
plasia of the sphenoid wing; and VII) a first-degree relative with NF-1 
fulfilling the above criteria.
A variety of vascular lesions have been observed in patients with 
NF-1, such as arterial occlusion, aneurysms, pseudoaneurysms, steno-
sis, fistulae and ruptures. Although the arterial system is more com-
monly affected, lesions of the venous system have also been observed.3 
The main characteristic of vascular lesions in patients with NF-1 is 
occlusion of the lumen and hyperplasia of the intima wall. Based on 
microscopic evaluation of the affected vessels, it has been proposed 
that the vasculopathy of NF-1 patients results from abnormal neu-
rofibromin function that leads to excessive proliferation of vascular 
smooth muscle cells during normal maintenance of the vessel. Con-
versely, even though neurofibromin is known to be expressed in vas-
cular smooth muscle cells, little is known about its function relating 
to controlling endothelial cell proliferation.8 Interestingly, despite the 
proximity of the NF-1 gene (17q11.2) to the gene for familial moy-
amoya disease (17q25), NF-1 does not participate in occurrences of 
moyamoya disease.9
MMD was first described in 1957 and, since this initial report, 
much has been described regarding the clinical characteristics of the 
disease. Nonetheless, its etiology continues to be ill-defined.10 MMD is 
more frequently observed in the Japanese population, with an estimated 
incidence of one new case per 1,000,000 individuals per year. MMD 
more frequently affects children younger than 10 years.11
In children, cerebral ischemia has been the most common presen-
tation of MMD. In a study on 143 pediatric patients with MMD in 
North America, Scott et al.12 observed that nearly all the patients had 
clinical symptoms of aneurysm or transitory ischemic attacks, and simi-
lar results have been reported in European studies.13 In a cohort study 
on 316 children with NF-1, Rosser et al.3 observed cerebral vasculopa-
thy in eight of them (2.5%), with only two cases (0.6%) also present-
ing MMS. 
Most patients with NF-1 associated with vascular lesions are asymp-
tomatic.14 When symptoms are present, they include neurological find-
ings such as paresthesia, headache, epileptic seizures, hemianopsia, ny-
stagmus, aphasia, dysphasia and borderline mental level.15 Surgical in-
tervention has become the treatment of choice for patients with MMD, 
and particularly surgical revascularization in order to increase the blood 
flow to the hypoperfused cortex.5,16
CONClUSION
The present report describes an additional case of associated NF-1 
and MMS in a pediatric patient. Although this association is relatively 
uncommon, MMS is a potentially severe disease that may evolve with 
an unfavorable neurological course. Thus, the hypothesis that this as-
sociation may be present should be considered in cases of patients with 
NF-1 and focal neurological symptoms, so that proper care can be 
promptly provided.
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